Search company, investor...



Series A | Alive

Total Raised


Last Raised

$100K | 25 yrs ago

About Lysis

Lysis offers Content Management solution for digital TV operators, content providers and broadcasters.

Headquarters Location


Missing: Lysis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Lysis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Lysis News

Global Cell Lysis Market to Surpass US$ 7,335.40 Million by 2030 - Coherent Market Insights

Jul 11, 2022

News provided by Share this article Share this article SEATTLE, July 11, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global cell lysis market is estimated to be valued at US$ 3,781.33 million in 2022 and is expected to exhibit a CAGR of 8.6% during the forecast period (2022-2030). Key Trends and Analysis of the Global Cell Lysis Market: Major players operating in market are focusing on adopting strategies such as product launch, which is expected to drive market growth over the forecast period. For instance, in April 2018, BD, (Becton, Dickinson and Company), a medical technology company, announced the launch of the BD FACSymphony(TM) S6 cell sorter. The new platform leverages the high parameter capabilities of the BD FACSymphony cell analyzer, giving researchers the ability to sort cell populations to better understand cell phenotypes for immunology and multi-omics research. Request Sample Copy of this Report @ Key Market Takeaways: Global cell lysis market is expected to exhibit a CAGR of 8.6% during the forecast period due to increasing prevalence of infections. For instance, according to the World Health Organization Facts Sheet 2022, around 296 million people were living with chronic hepatitis B infection in 2019 globally. Among product types, the Consumables segment is expected to dominate the segment growth over the forecast period, due to rapid development of different types of consumables by key players in market. For instance, in March 2021, Promega Corporation, a manufacturer of enzymes and other products for biotechnology and molecular biology, had released XpressAmp Direct Amplification Reagents that facilitate RNA extraction-free sample preparation that is automation-friendly. With this innovation, laboratories testing for COVID-19 have a new tool that enables them to skip the potentially bottlenecked RNA extraction step of the workflow and move directly to polymerase chain reaction (PCR) amplification. On the basis of cell types, the Mammalian Cells segment is expected to dominate the segment growth over the forecast period, because mammalian culture systems are extensively used during the bio-manufacturing of viral vaccines, therapeutic proteins, and other recombinant products. Moreover, key players in market are providing a range of mammalian lysis reagents, which is expected to drive market growth. For instance, Merck Millipore, the life science business of Merck KgaA, provides a range of mammalian lysis reagents that are utilized for the preparation of mammalian phosphorylated, cytosolic, and nuclear proteins. Some products of  the company include CytoBuster protein extraction reagent, NucBuster protein extraction kit, PhosphoSafe extraction reagent, and ProteoExtract kits. Key players operating in the global cell lysis market include Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Merck KgaA, QIAGEN, Roche Molecular Systems, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., and Qsonica. Request for Customization @ Instruments Mammalian Cells Academic and Research Labs North America Buy this Complete Report Now @ About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Contact Us:

Lysis Frequently Asked Questions (FAQ)

  • What is Lysis's latest funding round?

    Lysis's latest funding round is Series A.

  • How much did Lysis raise?

    Lysis raised a total of $100K.

  • Who are the investors of Lysis?

    Investors of Lysis include Endeavour Vision.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.